Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 10, 2003, Pages 421-440

  Breuer, H W M ^a  

^a St Carolus Krankenhaus   (Germany)

Author keywords

Acarbose; Cardiovascular disease; Impaired glucose tolerance; STOP NIDDM; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; VOGLIBOSE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LONG TERM CARE; METEORISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; WEIGHT GAIN;

EID: 0141996261     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41421     Document Type: Review

References (127)

1. Adler A 2002 Obesity and target organ damage: diabetes. Int J Obes Relat Metab Disord 26(Suppl 4): S11-S14
2. Ahr HJ, Boberg M, Krause HP, Maul W, Müller FO, Ploschke HJ, Weber H, Wünsche C 1989 Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittelforschung 39: 1254-1260
3. American Diabetes Association 2003 Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (Suppl 1): S33-S50
4. Avignon A, Radauceanu A, Monnier L 1997 Nonfasting plasma glucose is a better market of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: 1822-1826
5. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E 1998 High plasma glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21: 360-367
6. 1c. IOEZ Study Group. Diabetes Care 23: 1236-1241
7. Bayraktar M, Van Thiel DH, Adalar N 1996 A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19: 252-254
8. Beks PH, Mackaay AJ, de Vries H, de Neeling JN, Bouter LM, Heine RJ 1997 Carotid artery stenosis is related to plasma glucose level in an elderly Caucasian population: the Hoorn Study. Diabetologia 40: 290-298
9. Bischoff H 1994 Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 24 (Suppl 3): 3-10
10. Braun D, Schönherr U, Mitzkat HJ 1996 Efficacy of acarbose mono-therapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinology and Metabolism 3: 275-280
11. Breuer HWM 2000 The postprandial blood glucose level. A new target for optimizing treatment of diabetes mellitus. Eur Heart J 2 (Suppl D): 36-38
12. Buse J, Hart K, Minasi L 1998 The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther 20: 257-269
13. Buteau J, Foisy S, Joly E, Prentki M 2003 Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132
14. Calle-Pasqual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP 1996 Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 22: 201-202
15. Carey AL, Lamont B, Andrikopoulos S, Koukoulas S, Proietto J, Febbraio MA 2003 Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302: 837-840
16. Caro JJ, Ward AJ, O'Brien JA 2002 Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 25: 476-481
17. Centres for Disease Control and Prevention 1999 Diabetes Surveillance Report. US Department of Health and Human Services, Atlanta
18. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M 1996 Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 39: 469-473
19. Ceriello A 2001 Mechanisms of tissue damage in the postprandial state. Int J Clin Pract Suppl 123: 7-12
20. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, Panelo AA, Kim DK, Embong M 1998 An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 21: 1058-1061
21. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM 1994 The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121: 928-935
22. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM 1996 The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19: 1190-1193
23. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M 1998 The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21: 1720-1725
24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M 2002a Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077
25. Chiasson JL, Josse RG, Gomis R Hanefeld M, Karasik A, Laakso M 2002b Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM trial (Poster). 38th EASD Annual Meeting, Budapest, Hungary, Sept. Poster C312
26. Chiasson JL, Josse RG, Gomis R Hanefeld M, Karasik A, Laakso M 2002c Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM trial. Diabetologia 45: A104
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M 2003 Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP NIDDM trial. JAMA 290: 486-494
28. Coniff RF, Shapiro JA, Seaton TB 1994 Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 154: 2442-2448
29. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB 1995a Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 18: 817-824
30. Coniff RF, Shapiro JA, Seaton TB, Bray GA 1995b Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98: 443-451
31. Coniff RF, Krol A 1997 Acarbose: a review of US clinical experience. Clin Ther 19: 16-26
32. Costa B, Pinol C 1997 Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 38: 3340
33. Coutinho M, Gerstein HC, Wang Y, Yusuf S 1999 The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 233-240
34. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A 2002 Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 28: 195-200
35. Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med 346: 393-403
36. Dimitriadis G, Tessari P, Go V, Gerich J 1982 Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man. Metabolism 31: 841-843
37. Dodson PM 2002 Hypertension and diabetes. Curr Med Res Opin 18 (Suppl 1): S48-S57
38. Donahue RP, Abbott RD, Reed DM, Yano K 1987 Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36: 689-692
39. Enç FY, Imeryuz N, Akin L, Turoglu T, Dede F, Haklar G, Tekesin N, Bekiroglu N, Yegen BC, Rehfeld JF, Holst JJ, Ulusoy NB 2001 Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 281: G752-G763
40. Erlinger TP, Brancati FL 2001 Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 24: 1734-1738
41. Ferey-Roux G, Perrier J, Forest E, Marchis-Mouren G, Puigserver A, Santimone M 1998 The human pancreatic alpha-amylase isoforms: isolation, structural studies and kinetics of inhibition by acarbose. Biochim Biophys Acta 1388: 10-20
42. Ferner RE 1988 Oral hypoglycemic agents. Med Clin North Am 72: 1323-1335
43. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T 1998 European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 35: 34-40
44. Fölsch UR, Ebert R, Creutzfeldt W 1981 Response of serum levels of gastric inhibitory polypeptide and insulin to sucrose ingestion during long-term application of acarbose. Scand J Gastroenterol 16: 629-632
45. Gœde P, Pernille V, Larsen N, Jensen GV, Parving HH, Pedersen O 2003 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393
46. Gentile S, Turco S, Guarino G, Oliviero B, Rustici A, Torella R 1999 Non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose. Ann Ital Med Int 14: 7-14
47. German Diabetes Society (Deutsche Diabetes-Gesellschaft) 2002a Diabetes mellitus type 2. AWMF online, http://www.uni-dusseldorf.de/WWW/AWMF/11/diab 012k.htm, accessed 12 February 2003
48. German Diabetes Society (Deutsche Diabetes-Gesellschaft) 2002b Statement referring to the German Positive List. [letter)
49. Groop PH, Groop L, Totterman KJ, Fyhrquist F 1986 Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol (Copenh) 112: 361-366
50. Guvener N, Gedik O 1999 Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 36: 93-97
51. Haffner SM, Hanefeld M, Fischer S, Fucker K, Leonhardt W 1997 Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 20: 1430-1434
52. Halimi S, Le Berre MA, Grange V 2000 Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 50: 49-56
53. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fucker K 1991 Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732-737
54. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J 1996 Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39: 1577-1583
55. Hanefeld M 2002 Postprandial hyperglycemia: noxious effects on the vessel wall. Int J Clin Pract 129 (Suppl): 45-50
56. Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, Heyen P, Mahla G, Schmidt C, Schulze-Schleppinghof B, Steger-Johannsen G 1999 Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 12: 277-285
57. Hoffmann J, Spengler M 1994 Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 17: 561-566
58. Hoffmann J, Spengler M 1997 Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 103: 483-490
59. Hollander P 1992 Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 44 (Suppl 3): 47-53
60. Holman RR, Cull CA, Turner RC 1999 A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22: 960-964
61. Holstein A, Nahrwold D, Hinze S, Egberts EH 1999 Contra-indications to metformin therapy are largely disregarded. Diabet Med 16: 692-696
62. Holt PR, Atillasoy E, Lindenbaum J, Ho SB, Lupton JR, McMahon D, Moss SF 1996 Effects of acarbose on fecal nutrients, colonic pH, and short-chain fatty acids and rectal proliferative indices. Metabolism 45: 1179-1187
63. Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278
64. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, Sakamoto N 1993 Long-term effect of acarbose on glycemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled, double-blind study. Diabet Med 10: 134-138
65. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE 2002 Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25: 1129-1134
66. Josse RG, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, Leiter LA, Maheux P, Tessier D, Wolever TM, Gerstein H, Rodger NW, Dornan JM, Murphy LJ, Rabasa-Lhoret R, Meneilly GS 2003 Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 59: 37-42
67. Kado S, Murakami T, Aoki A, Nagase T, Katsura Y, Noritake M, Matsuoka T, Nagata N 1998 Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 41: 49-55
68. Kawamura T, Egusa G, Fujikama R, Watanabe T Oda K, Kataoka S, Takayama D, Kubo K, Yamamoto S, Noma K, Orita R, Yamakido M 1998 Effect of acarbose on glycemic control and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Current Therapeutic Research 59: 97-105
69. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J 1998 Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 21: 2056-2061
70. Kovacevic I, Profozic V, Skrabalo Z 1997 Multicentric clinical trial to assess efficacy and tolerability of acarbose in comparison to glibenclamide and placebo. Diabetologia Croatica 26: 83-89
71. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE 2002 Body mass index and the risk of stroke in men. Arch Intern Med 162: 2557-2562
72. Laube H, Linn T, Heyen P 1998 The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 106: 231-233
73. Laube H 2002 Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 22: 141-156
74. Lebovitz HE 1997 α-Glucosidase inhibitors. Endocrinol Metab Clin North Am 26: 539-551
75. Lebovitz HE 1998 Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 6: 132-145
76. Lee SM, Bustamante SA, Koldovsky O 1983 The effect of alpha-glucosidase inhibition on intestinal disaccharidase activity in normal and diabetic mice. Metabolism 32: 793-799
77. Lindström J, Tuomilehto J, Spengler M 2000 Acarbose treatment does not change the habitual diet of patients with type 2 diabetes mellitus. The Finnish Acarbose Study Group. Diabet Med 17: 20-25
78. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J 1997 Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 20: 163-169
79. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB 2002 The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (Suppl 3): S434-S442
80. Malaguarnera M, Giugno I, Panebianco MP, Pistone G 1998 Beneficial effects of acarbose on familiar hypertriglyceridemias. Int J Clin Pharmacol Ther 36: 441-445
81. May C 1995 Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes mellitus (NIDDM) treated with sulfonylureas. Diabetes Stoffwechsel 4: 3-8
82. Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, Nathan DM, Wilson PW, O'Donnell CJ 2002 Coronary artery calcification in type 2 diabetes and insulin resistance: the Framingham Offspring Study. Diabetes Care 25: 1313-1319
83. Meneilly GS, Tessier D 1995 Diabetes in the elderly. Diabet Med 12: 949-960
84. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D 2000 Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23: 1162-1167
85. Mertes G 2001 Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 52: 193-204
86. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22-29
87. Monnier L 2000 Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 30 (Suppl 2): 3-11
88. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117
89. Phillips P, Karrasch J, Scott R, Wilson D, Moses R 2003 Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 26: 269-273
90. Pinol C, Guardiola E, Soler J, Cano F, Hernandez Mijares A, Jiménez A, de Leiva A, Arroyo JA 1998 A double-blind, randomized, placebo-controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients. Diab Nutr Metab 11: 242-248
91. Polonsky KS, Given BD, Van Cauter E 1988 Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442-448
92. Polonsky KS, Sturis J, Bell GI 1996 Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta-cell to compensate for insulin resistance. N Engl J Med 334: 777-783
93. Pyörälä M, Miettinen H, Laakso M, Pyörälä K 2000 Plasma insulin and all-cause, cardiovascular, and non-cardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 23: 1097-1102
94. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W 1995 Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896
95. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ 1990 Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl 3): 32-36
96. Rosak C, Haupt E, Walter T, Werner J 2002 The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive plasma glucose lowering effect and decreased hypoglycemia. Diabetes Nutr Metab 15: 143-151
97. Rosenbaum P, Peres RB, Zanella MT, Ferreira SR 2002 Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Braz J Med Biol Res 35: 877-884
98. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J 1998 Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 21: 2050-2055
99. Rosenthal JH, Mauersberger H 2002 Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 22: 695-701
100. Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengul A Demirel HO, Karsidag K, Dinccag N, Yilmaz MT 2001 Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 16: 296-306
101. Santeusanio F, Ventura MM, Contadinbi S, Compagnucci P, Moriconi V, Zaccarini P, Marra G, Amigoni S, Bianchi W, Brunetti P 1993 Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes Nutr Metab 6: 147-154
102. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL 2001 Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 24: 1397-1402
103. Scheppach W, Fabian C, Ahrens F, Spengler M, Kasper H 1988 Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 95: 1549-1555
104. Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T 1999 Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract 43: 179-185
105. Shuldiner AR, Yang R, Gong DW 2001 Resistin, obesity and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N Engl J Med 345: 1345-1346
106. Soonthornpun S, Rattarasarn C, Thamprasit A, Leetanaporn K 1998 Effect of acarbose in treatment of type 2 diabetes mellitus: a double-blind, crossover, placebo-controlled trial. J Med Assoc Thai 81: 195-200
107. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W 1999 Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 46: 23-27
108. Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J 1999 Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab 1: 215-220
109. 1c level. Diabetes Care 23: 1830-1834
110. The DECODE Study Group 1999 Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 354: 617-621
111. The DECODE Study Group 2003 Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26: 61-69
112. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
113. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197
114. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2003 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26: S5-S20
115. Tominaga M, Eguchi H, Monaka H, Igarashi K, Kato T, Sekikawa A 1999 Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924
116. Turner RC, Cull CA, Frighi V, Holman RR 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281: 2005-2012
117. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 12: 837-853
118. Unwin N, Shaw J, Zimmet P, Alberti G 2002 International Diabetes Federation IGT/IFG Consensus Statement. Report of an Expert Consensus Workshop 1 - 4 August 2001, Stoke Poges, UK. Diabetic Medicine 19: 708-723
119. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ 1999 Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42: 926-931
120. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P 2002 Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 55: 99-103
121. Weaver GA, Tangel CT, Krause JA, Parfitt MM, Jenkins PL, Rader JM, Lewis BA, Miller TL, Wolin MJ 1997 Acarbose enhances human colonic butyrate production. J Nutr 127: 717-723
122. Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H, Zaojun Y, Fan W, Guangwei L, Xiaoren P 2001 The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multi-center prospective study. Chin J Endocrinl Metab 17: 131-136
123. Willms B, Ruge D 1999 Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 16: 755-761
124. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB 2002 Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162: 1867-1872
125. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH 1997 Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 21: 756-763
126. Zick R, Schnitger F 2001 Acarbose - Leitfaden für die Praxis. Verlag Kircheim, Mainz
127. Zraika S, Dunlop M, Proietto J, Andrikopoulos S 2002 Effects of free fatty acids on insulin secretion in obesity. Obes Rev 3: 103-112